Small-Cap on Korea Invest Insights

KOSDAQ Coverage Gaps: 52 Covered Names and 9 Hidden Small-Caps

Thu, 23 Apr 2026 18:00:00 +0900

Series — KOSDAQ Structural 2026 (Part 4 of 4, bonus) ① Capital Inflow Triggers & VC Ranking — the policy setup ② IPO Class of 2023-2026: Where the Tenbaggers Live — the post-IPO winners ③ KR Tenbaggers Full 10× Census — the realized 3-year winners ④ This post — where sell-side isn’t yet, and why that matters

The Premise

If tenbaggers cluster, so does sell-side attention. And the gap between where analysts publish and where the structural winners sit is where variant perception lives.

We pulled every broker report filed to Hankyung Consensus (한경컨센서스) over the trailing 3 months — Jan 23 to Apr 23, 2026 — across 11 brokers that feed the platform (LS, Eugene, SK, iM, Meritz, Yuanta, Hanwha, IBK, Daishin, Sangsangin, KoreaIR). Only 52 KOSDAQ names got ≥2 broker coverage in that window.

That’s out of ~1,777 KOSDAQ stocks.

Data Caveat (Say It Once, Loud)

Hankyung does not include Samsung, Mirae Asset, Kiwoom, NH, Hana, Shinhan, KB, Korea Investment, DB, or Daol — 10+ major houses. So “2 brokers on Hankyung” typically maps to 4-6 actual brokers in the real market. That matters for a few names below where the published count understates the truth.

[Fact] 52 names passed the 2-broker / 3-month threshold on Hankyung
[Inference] True market-wide coverage is ~1.8-2.5× the reported number
[Blocked] Target-price consensus and recommendation distributions are not computable from this dataset (needs FnGuide)

The Sector Map — 52 Names, 8 Buckets

Sector	Count	Share	Notable density
Electronics / Semis	13	25%	Ecopro BM, Leeno, Duksan Neolux
Machinery / Equipment	10	19%	Wonik IPS, ISC, Tes
Bio / Pharma	10	19%	ABL Bio, Classys, Hugel
Media / Ent / Games	6	12%	SM (8 brokers, 14 reports), YG (7/12), JYP (5/7)
IT Services / SW	5	10%	Pearl Abyss, Dear U, Neowiz
Defense	3	6%	Daeyang, Victek, Coats Technologies
Education / Services	2	4%	Megastudy, JLS
Financial / Consumer / Chemical	3	6%	Hecto Financial, Silicon2, Sungeel HiTech

Market-cap distribution:

L (>1T KRW): 27 names (52%)
M (300B-1T): 16 (31%)
S (100-300B): 8 (15%)
XS (<100B): 1 (2%)

The structurally interesting bucket is the 9 small-caps ≤300B KRW with ≥2 brokers. That combination — small enough to be inefficient, covered enough to have a publishable thesis — is where variant perception can actually be framed.

The 9 Small-Caps

Ticker	Name	Cap (B KRW)	Coverage	Thesis keyword
357580	Amosense	216	SK, Yuanta (+ Hanyang)	SOFC ceramic substrate, fuel cell / auto electronics
448710	Coats Technologies	124	iM, Eugene, Yuanta (+ Hi)	K2 SBC, Cheongung-II, ASP lift, site visits
108380	Daeyang Electric	298	IBK, LS	14-year range breakout, corporate restructuring
321550	Tiumbio	271	Eugene, KoreaIR	Merigolix Europe licensing inflection
065450	Victek	169	SK, Yuanta	Structural EW niche, new growth drivers
232680	Raon Robotics	213	Yuanta, KoreaIR	Semi fab robots, global expansion
263860	Genians	145	Eugene, KoreaIR	NAC/EDR #1, capex-to-operating-leverage
078890	Gaon Group	125	Meritz, Yuanta	STB NDR, strong demand, earnings turn
040420	Sangsang JLS	94	LS, KoreaIR	Education dividend, margin improvement

One structural read-through: 5 of 9 have KoreaIR Council as one of the two “brokers.” KoreaIR publishes sponsored/initiation research — quality varies, but it’s not an independent second opinion. Subtract that, and the real publishable-thesis count drops to 1 broker + initiation note for many of these. That’s thinner than the raw coverage implies — and thinner coverage is where variant perception is cheapest.

Six Thesis Archetypes

A — Defense Export, Tier-2 Beneficiary (2 names)

Name	Choke point	Priced-in
Coats Technologies	Sole domestic supplier of K2 SBC; Cheongung-II integrated operating computer localization complete	Medium
Victek	Electronic warfare (EW) domestic niche	Medium-low

Coats Technologies printed 1,190B KRW order backlog at 2024Q3 with UAE / Saudi / Iraq entering volume production in 2026. [Fact] Cheongung-II hit 100% intercept rate on eight cruise missiles in a March 2026 UAE engagement (MBC, FT) — the kind of live-combat validation that historically re-rates defense export names globally.

The tier-1 names (Hyundai Rotem, LIG Nex1) are priced-in. Coats is the lock-in supplier one layer down the stack.

Victek’s “structurally growing EW niche” is softer — analyst defensive framing rather than a numbers-backed thesis. Needs quant validation.

B — AI / Datacenter Power Chain (1 name)

Name	Choke point	Priced-in
Amosense	Sole domestic manufacturer of ceramic electrolyte substrate for Bloom Energy SOFCs	Low

This is the strongest choke-point candidate in the entire set.

Bloom-Oracle 2.8GW agreement (Apr 2026)
Bloom-AEP $2.65B agreement (Jan 2026)
Hanyang Securities: Amosense SOFC revenue 100B KRW in 2026 → 400B KRW in 2027 (4×)
Bloom’s strategic China supply-chain diversification = direct Amosense tailwind
Peers in the Bloom supply chain (Vinatech, Kosess) have already rallied; Amosense is still sitting at 160-220B KRW market cap

This is the classic NRE-to-volume J-curve: 2024-25 = pilot, 2026 = first volume (100B), 2027 = scale (400B). Same shape as the ADT / Gaonchips cycle a few years back. The consensus hasn’t reflected the 2027 step-up yet.

C — Value-Up / Activist (1 name)

Name	Trigger	Priced-in
Daeyang Electric	Quad Asset Management shareholder proposal → Jan 29, 2026 disclosure: Daeyang-Jeonjang stake acquisition, subsidiary conversion	Medium-high

Broke a 14-year range in January. IBK target price 46,000 KRW (+20% revision), LS 40,000. Already hit 52-week high at 31,500 and is digesting. Most of the first leg is priced in. The second catalyst — actual buyback cancellation or dividend expansion — is the checkpoint.

Warning: don’t generalize this into “value-up = automatic rerating.” It worked here because the activist forced a specific, disclosable action. Without that forcing function, a governance thesis is just vibes.

D — Biotech Pipeline Inflection (1 name)

Name	Event	Priced-in
Tiumbio	Merigolix Europe licensing	Low

Binary. L/O lands → re-rating. L/O falls through → drawdown. Typical small-cap biotech shape. Latest publishable research is Eugene’s Apr 13 NDR note; KoreaIR’s piece is from Feb 25. [Speculation] on the outcome.

E — Niche Tech Leadership (3 names)

Name	Positioning	Priced-in
Raon Robotics	Global push in semi-fab robots	Low
Genians	NAC / EDR #1 domestically	Medium
Gaon Group	STB / networking earnings turn	Medium

These are the “quality small-cap” cluster. Raon’s “aspirations” framing tells you earnings are still lagging the story. Genians is a slow compounder — the edge is in the operating-leverage step-up if enterprise security capex cycle turns. Gaon is cycle-sensitive; NDR narrative (“strong demand”) needs P&L confirmation.

F — Dividend / Low-Growth (1 name)

Name	Positioning	Priced-in
Sangsang JLS	Education sector dividend play	Medium

94B KRW cap, decent dividend + improving margins, minimal growth. Not alpha — carry. Belongs in a yield sleeve, not a variant-perception book.

Variant Perception Ranking

Rank	Name	Trade type	Core reason	Horizon
1	Amosense (357580)	Idiosyncratic Alpha	Bloom supply-chain peers already rallied, Amosense lagging; 4× SOFC revenue step-up 2026→2027 not in consensus	6-12M
2	Coats Technologies (448710)	Idiosyncratic Alpha	Tier-1 defense priced-in; sole-supplier SBC lock-in + Cheongung-II global demand post-UAE validation	6-12M
3	Tiumbio (321550)	Speculation	Europe L/O binary — re-rates hard up or hard down	3-9M
4	Raon Robotics (232680)	Beta Trade	Semi-fab capex cycle exposure	12M+
5	Victek (065450)	Idiosyncratic Alpha	EW niche — needs numbers	12M+
6	Genians (263860)	Quality Compounder	Slow security-SW compounder	24M+
7	Gaon Group (078890)	Beta Trade	STB earnings turn — cycle-sensitive	6M
8	Daeyang Electric (108380)	Idiosyncratic Alpha (late)	First-leg done; waiting on second catalyst	3-6M
9	Sangsang JLS (040420)	Carry	Dividend play; not alpha	Indefinite

Other Structural Observations

Entertainment coverage is anomalously deep. SM at 8 brokers / 14 reports and YG at 7 / 12 is mid-cap-index-level density. Within the same sector, SAMG Entertainment at 2 / 2 is the “quasi-coverage gap” candidate — covered enough to have a framework, sparse enough that a re-rating under a hit IP thesis has room to run.

Structural coverage deserts — consumer, chemicals, autos, transport, construction. 0-1 names each. Partly because KOSDAQ listings in those sectors are sparse to begin with, but for names like Silicon2 (3T KRW cap, single broker coverage), the absence of peer benchmarking is a real risk — analysts cannot triangulate without comparables.

Defense small-caps are getting real traffic. Three names in the 100-300B cap range, all with recent notes (Apr 7, Apr 15, Apr 17). Coats Technologies at 124B KRW with 3 brokers is coverage-density-per-cap that typically precedes promotion into the sell-side consensus proper.

KoreaIR-Council inflation. ~5 of the 9 small-caps have one of their two “covers” as KoreaIR Council. That is an initiation-style sponsored research product — useful, but not independent second-opinion coverage. Filtering it out, most of these names are really “1 broker + initiation note” — meaningfully thinner than the raw count suggests, and a better reflection of where the variant-perception opportunity actually lives.

Invalidation Triggers

Because small-cap theses die quietly, write the kill condition up front.

Name	Kill trigger
Amosense	Bloom-Oracle / AEP supply schedule slips ≥6 months; or Bloom re-expands Chinese supply publicly
Coats Technologies	2026H1 order backlog drops below 1,000B; Polish K2 Phase-2 contract negotiations break
Daeyang Electric	No concrete buyback-cancellation or dividend-expansion announcement by end-2026
Tiumbio	Merigolix Europe negotiations halt, or clinical data turns negative

TL;DR

KOSDAQ sell-side coverage is concentrated in 52 names — just 3% of the index. Within that, 9 small-caps (≤300B KRW) cluster into 6 thesis archetypes: defense tier-2, AI power chain, activist value-up, biotech inflection, niche tech, and dividend carry.

Two names stand out on the choke-point / priced-in matrix:

Amosense — Bloom Energy ceramic-substrate bottleneck, 4× revenue step-up not in consensus
Coats Technologies — K2 SBC sole supplier + Cheongung-II live-combat validation

Daeyang Electric already ran on the value-up story — most of the first-leg move is priced in; the second catalyst is the decision point. The rest sit in weaker variant-perception positions: Tiumbio is binary, Raon is a beta trade, Sangsang JLS is carry.

If sell-side hasn’t written it down, it isn’t priced. These 9 names are the cheapest option we found on that asymmetry.

This bonus post closes the KOSDAQ Structural 2026 series. Part 1: VC ranking. Part 2: IPO tenbagger class. Part 3: Full 10× census.

Disclaimer: For research and information purposes only. Not investment advice. Names cited are for analytical illustration; readers should perform their own due diligence and consult licensed advisors before any investment decision.

KOSDAQ IPO Tenbaggers: 259 Firms, 3 Buckets and 11 Names

Wed, 22 Apr 2026 10:30:00 +0900

📚 Series 2/4: KOSDAQ Structural Deep-Dive — series hub →

Second entry. Prior: Korea’s 2026 KOSDAQ Policy Package — A VC-Practitioner Ranking of the Ten Active Capital-Inflow Triggers mapped the money-in channels. This post asks the opposite question: once the money arrives, where does it actually compound? The answer from the 2023-2026 new-listing cohort is surprisingly concentrated.

TL;DR

Of 308 KOSDAQ new listings from 2023-2026, exactly 49 are SPACs (identified by “SPAC” in the Korean ticker name). Strip those out and the real operating universe is 259 firms.

From that 259:

39 firms (15%) have returned +100% or more since IPO
33 firms (13%) are down -50% or worse
53% are still below the IPO price
44% of the winners cluster in 3 sector buckets — R&D (pharma pipeline), semiconductors, medical devices. Those three buckets hold 48 firms, barely 19% of the universe, but 17 of the 39 tenbaggers came from them.

The single strongest numerical signal: firms with YoY revenue growth above 200% show a 57% tenbagger hit rate (4 of 7). The next bucket (50–200% growth) drops to 29%. Above 200% is effectively a structural filter.

Below: the full decomposition, then an 11-name Tier 1 shortlist to move into qualitative review.

1. Redefining the universe: SPACs cleanly removed

The cleanest SPAC filter is the Korean ticker-name rule: any listed shell with “스팩” (SPAC) in the name. That removes 49 names across four cohorts — most heavily from the 2024 cohort (36 SPACs alone).

Names sometimes flagged as “shells” but which are genuine operating businesses and therefore kept: LB Investment, HB Investment, Capstone Partners (all three are VC fund managers with real carry revenue), Hanpass (FX remittance fintech), Terra View. These stay in.

Cohort	Raw B-universe	After SPAC removal
2023 IPOs	101	92
2024 IPOs	123	87
2025 IPOs	79	75
2026 IPOs (YTD April)	5	5
Total	308	259

2. Year-by-year post-IPO performance (operating firms only)

Cohort	N	Median revenue (KRW bn)	Operating-profit firms	Median ADT20 (KRW bn/day)	Median return since IPO	+100% firms	+500% firms	Loser rate	Median current drawdown
2023	92	32.9	34%	1.15	+0.4%	11 (12%)	0	49%	-29%
2024	87	26.9	49%	1.24	-25.5%	16 (18%)	4	61%	-42%
2025	75	50.1	39%	2.02	-20.2%	12 (16%)	1	57%	-48%
2026	5	35.2	60%	24.70	-40.7%	0	0	60%	-41%

Three observations that pay off later:

2024 is the paradox cohort. Median return -25.5% (worst of any year), but all four +500% winners came from 2024 — Sceers Medical, D&D Pharmatech, Samhyun, HVM. Classic high-variance distribution: the median gets crushed while the right tail produces the biggest hits.
2025 is the “expensive IPO of mature companies” cohort. Median revenue 50.1B KRW (highest of any year — these were real companies at scale), but -48% median drawdown from peak. Pricing was rich; de-rating is mechanical. The distribution suggests 12–18 months out, this cohort should throw off re-entry opportunities at de-rated multiples.
Operating-profit rate isn’t a quality signal here. 2024 had the highest profitability (49% of listings profitable at IPO) yet the weakest post-IPO returns. High profitability at listing correlates with “mature companies priced near fair value” — exactly the opposite of where tenbaggers come from.

3. Sector bucket performance (N≥8, covering 139 of 259 firms)

Sector	N	Median rev (bn)	Profit rate	Median ROE	Median P/E	Median YoY growth	Median return	p90 return	+100% hits	Loser rate
R&D (bio pipeline)	18	4.3	11%	-44%	55	+9%	+51.5%	+312%	7	33%
Semiconductors	16	20.2	19%	-18%	59	+6%	+47.3%	+215%	5	38%
Medical devices	14	20.6	50%	+3%	49	+36%	+14.2%	+260%	3	43%
Electronic components	13	81.9	46%	0%	44	+9%	-6.7%	+80%	1	54%
Special-purpose machinery	22	29.9	32%	-2%	26	-3%	+0.2%	+52%	2	50%
General machinery	9	45.0	44%	-5%	26	+14%	-17.5%	+21%	0	67%
Software	36	19.6	28%	-8%	25	+11%	-17.6%	+67%	2	61%
Other chemicals (incl. EV battery)	11	28.5	82%	+8%	42	-8%	-42.2%	-17%	1	91%

Three winner buckets

Bio R&D + Semiconductors + Medical devices = 48 firms, 19% of universe, but 17 of the 39 +100% hits (44%). That concentration is not noise — it reflects a structural reality:

Bio R&D winners compound on clinical milestones and out-licensing deals, not current revenue. So a firm can have 4.3bn KRW median revenue and still hit +312% at the p90.
Semiconductor winners ride specific cycles: HBM-adjacent, AI-server SSD, wafer-back-end. Five listings hit +100% with median P/E of 59x — the market pays for the asymmetric call on new memory architectures.
Medical devices have the highest profitability (50% profit rate) and a +260% p90. That combination is rare. Korean medical devices with FDA approval + US distribution are structurally underpriced because the local market doesn’t know how to value US-scale med-tech.

Two loser buckets

Software (36 firms) + Other chemicals (11 firms) = 47 firms, explaining most of the loser population.

Software is the “AI premium paid at IPO” problem. 61% loser rate. Thin moats, low switching cost, and the “AI wrapper” narrative deflated as soon as enterprise buyers got sober in mid-2024.
Other chemicals is the 2차전지 (secondary battery) peak-out. 91% loser rate (10 of 11 down). Battery-material listings rode the 2022-2023 EV mania into IPO and then met the 2024-2025 demand correction head-on.

The middle zone

Special-purpose machinery, electronic components, general machinery — all “real revenue, boring multiples, mean-reverting performance.” Median revenue 30-82bn KRW (the biggest of any bucket) but median return near zero. This is the classic Korean KOSDAQ equipment/parts segment: legitimate businesses, cyclically priced, no asymmetric upside at IPO.

4. The DNA of the 39 winners

Looking across all +100% firms:

Characteristic	Count	Read
Operating-profit firms	13/39 (33%)	Profitability is not the signal. Two-thirds of tenbaggers are still losing money at IPO.
ROE > 10%	10	The 10 profitable-and-high-ROE winners are the “earnings-compounding” subset
YoY revenue growth > 50%	13	One-third have clear top-line explosions
Revenue ≥ 20bn KRW	22/38	58% have minimum size already
Revenue ≥ 100bn KRW	4/38	Large-revenue names are rare among tenbaggers — the universe favors smaller bases
Median P/E (profitable subset)	54.5×	Winners already trade at growth multiples

The single strongest signal: YoY revenue growth buckets

YoY revenue growth bucket	N	Median return	+100% hits	Hit rate
200%+	7	+106.8%	4	57%
50–200%	31	+8.5%	9	29%
20–50%	42	+10.5%	6	14%
0–20%	72	-8.2%	9	13%
-20–0%	66	-24.4%	6	9%
≤-20%	36	-22.8%	4	11%

The 57% hit rate for the 200%+ bucket is the single most concentrated signal in the data. Seven names — priority research targets. Caveat: n=7 is small; treat the number as a direction, not a probability estimate for the next cohort.

5. Top 10 winners — current state

Ticker	Sector	IPO	Return	Peak DD	Revenue (bn)	YoY growth
Sceers Medical	Medical device	2024-06	+1,111%	-31%	48.2	+495%
D&D Pharmatech	Bio R&D	2024-05	+1,011%	-27%	4.3	-62%
Samhyun	Auto parts	2024-03	+635%	-26%	95.0	-5%
HVM	Non-ferrous metals	2024-06	+614%	-19%	66.5	+47%
Rokit Healthcare	Medical supplies	2025-05	+526%	-38%	26.2	+100%
Tomocube	Optics	2024-11	+444%	-17%	11.3	+91%
Onconic Therapeutics	Bio R&D	2024-12	+421%	-14%	53.4	+261%
Sammi Metal	Metal fabrication	2025-12	+411%	-20%	73.8	-3%
Klobot	Software (robotics)	2024-10	+391%	-35%	41.4	+24%
Fadu	Semiconductor	2023-08	+338%	-14%	92.4	+112%

Notable pattern: 7 of the Top 10 are currently in -25% to -40% drawdown from their post-IPO peak. “One tenbagger move, then a 30% reset” is the modal pattern. From a re-entry-timing perspective, this is the window that matters most — the tenbagger already proved the structural story; the drawdown is about positioning, not about the thesis breaking.

Top losers — the opposite side: E8 (-87%, game/AI SW post-IPO dump), Chi Communication (-82%, China advertising), TDS Pharma (-80%, generics), DaeJin Advanced Materials (-77%, battery-materials loser), M83 (-69%, film production). Common pattern: story-driven overpricing → earnings vacuum → collapse.

6. From universe to shortlist: the Tier 1 11

Combining (a) the three winner buckets, (b) revenue in the 20-150bn KRW “meaningful but not saturated” zone, (c) clear top-line growth in the last 12 months, and (d) either ongoing drawdown (re-entry) or live catalyst (new positioning), the following 11 names emerge as Tier 1 for qualitative review.

Bio R&D (2)

#	Name	IPO	Rev (bn)	ROE	Return	DD	Thesis
1	Onconic Therapeutics	24-12	53.4	+24.6%	+421%	-14%	Subsidiary of Jeil Pharmaceutical. Jaktinib (reflux therapeutic) out-licensed to China and India, US trials advancing. Only profitable firm in the 18-stock bio R&D bucket with real revenue scale. Next leg needs additional out-licensing or US milestone.
2	D&D Pharmatech	24-05	4.3	-31.5%	+1,011%	-27%	GLP-1-based obesity and Parkinson’s pipeline. Already the biggest 2024 winner. Valuation stretched — next leg requires clinical data readout. Re-entry window is narrow.

Semiconductors (5)

#	Name	IPO	Rev (bn)	YoY	ROE	Return	3M	DD	Thesis
3	Green Resource	23-11	102.2	+452%	+15.9%	+151%	+193%	0%	Quartz/ceramic materials for semiconductor processes. Samsung/Hynix vendor. Revenue 4× explosion. Currently at fresh highs — entry should wait for correction.
4	Fadu	23-08	92.4	+112%	-131%	+338%	+186%	-14%	SSD controller SoC. Data-center/enterprise SSD (Meta-style) order recovery. Direct AI-server exposure.
5	Sapien Semiconductor	24-02	17.3	+116%	-33%	+140%	+11%	-14%	Micro-LED pixel driver IC. Apple Vision Pro / AR-glasses-class forward investment. Revenue inflection just starting.
6	Qualitas Semiconductor	23-10	5.4	-12%	-53%	+65%	+55%	-7%	SerDes (high-speed interconnect) IP. SK Hynix cooperation + HBM-adjacent SerDes demand. IP royalty model — likely J-curve inflection point.
7	Wavics	(listed in period)	40.7	—	—	—	+87%	—	RF GaN semiconductors. Defense + comms dual exposure. Only domestic mass producer of GaN-on-SiC.

Medical devices (4)

#	Name	IPO	Rev (bn)	YoY	ROE	Return	DD	Thesis
8	Sceers Medical	24-06	48.2	+495%	+52.8%	+1,111%	-31%	AI ECG monitoring device. Revenue + ROE + growth triple-compounding. Most structurally complete medical-device tenbagger. In -31% correction.
9	Livsmed	25-12	51.2	+89%	-21%	+17%	-36%	“ArtiSential” laparoscopic multi-articulating instrument. US/EU launch accelerating. Recent IPO + revenue 51bn + growth +89% + DD -36% — rare 4-factor alignment.
10	Nextbiomedical	24-08	16.5	+74%	0%	+135%	-37%	FDA-approved “Nexsphere” embolization product. US revenue ramp imminent.
11	Asterasys	25-01	37.9	+32%	+27.7%	+79%	-26%	HIFU ultrasound skin-treatment device “Liftera.” Korea / China / Middle East demand. Top-quartile ROE among profitable medical-device IPOs.

7. What this framework actually says

Question	Answer from the 259-firm backtest
Base rate of finding a +100% winner at KOSDAQ IPO	15% (39/259)
Base rate of finding a +500% winner	1.9% (5/259)
Worst cohort to chase	2024 at listing (median -25.5%, 61% losers — though the right-tail winners came from here)
Best cohort to hunt in right now	2025 (richest base — median revenue 50bn — currently at -48% median drawdown)
Single most predictive metric	YoY revenue growth ≥ 200% → 57% hit rate
Sectors to live in	Bio R&D, semiconductors, medical devices (44% of winners, 19% of universe)
Sectors to skip	Software (61% loser rate), secondary-battery chemicals (91% loser rate)

The framework isn’t a prediction engine. It’s a base-rate engine. It says: given how money has actually been made in new KOSDAQ listings over the last three years, these 11 names sit on more of the right factors than any others in the cohort. Qualitative review comes next — IR material, disclosure history, consensus positioning — and position sizing follows that.

8. Caveats and honest uncertainties

YoY growth percentages are noisy in bio R&D. Most have base revenues of 3-10bn KRW, so a “+7,800%” print (Algenomics) is the jump from 100M to 8bn — a milestone payment, not a business inflection. For bio names, look at absolute revenue + pipeline milestones, not YoY %.
Fundamentals are an 8-day snapshot. The ROE/P/E here come from the 2026-04-14 through 04-21 filings window. Next quarterly reports will reshuffle some of these names.
Green Resource, Fadu, Sonics — 3-month momentum ≥ +180%. Chasing these here carries a sharp drawdown risk. The Tier 1 placement reflects structural fit, not “buy now.”
Re-entry on past +1,000% winners. D&D Pharmatech and Sceers Medical have already delivered 10×. Another 5-10× from here requires a new catalyst — new market, new indication, new geography. Without it, the base case is mean reversion.
Consensus / target-price fields are empty in our data. Sell-side positioning isn’t reflected. IR contact and disclosure-level review is mandatory before sizing.

9. What’s next

This post closed the loop started by the VC-practitioner policy ranking: money-in channels → where the money actually compounds. Two pieces of the same structural view of KOSDAQ 2026.

Next on the research stack: Tier 1 single-name deep-dives — starting with the two names where the thesis is simultaneously (a) fundamentally strong, (b) technically in a constructive drawdown, and (c) within our existing framework. Onconic Therapeutics and Livsmed are the likely first targets.